Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 68001-368

12 FDA label images from Bluepoint Laboratories · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 68001-368). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical Structure (Duloxetine 01)
Chemical structure diagram of Duloxetine Hydrochloride showing the molecular arrangement including the naphthalene and thiophene rings, an ether oxygen, and an amine with hydrochloride salt.*
FDA Label Image

Figure 1 (Duloxetine 02)

Figure 1 (Duloxetine 02)
A line graph comparing the proportion of patients with relapse over time (in days) between placebo and duloxetine delayed-release capsules. The graph shows time from randomization to relapse on the x-axis and proportion of patients with relapse on the y-axis, with a solid line representing duloxetine and a dashed line for placebo.*
FDA Label Image

Figure 2 (Duloxetine 03)

Figure 2 (Duloxetine 03)
A Kaplan-Meier curve comparing the proportion of patients experiencing relapse over time between placebo and duloxetine delayed-release capsules. The x-axis represents time from randomization to relapse in days, and the y-axis shows the proportion of patients with relapse. The chart illustrates a lower relapse rate over time for the duloxetine delayed-release capsule group compared to placebo.*
FDA Label Image

Figure 3 (Duloxetine 04)

Figure 3 (Duloxetine 04)
A line graph showing the percentage of patients improved versus percent improvement in pain from baseline, comparing Duloxetine doses (60 mg BID, 60 mg QD, 20 mg QD) to placebo. The horizontal axis represents percent improvement in pain, and the vertical axis shows the percentage of patients improved. Four separate trend lines depict the results for each treatment group.*
FDA Label Image

Figure 4 (Duloxetine 05)

Figure 4 (Duloxetine 05)
A line graph showing percentage of patients improved versus percent improvement in pain from baseline. Three lines represent Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo, comparing patient improvement rates for each treatment over different pain improvement percentages.*
FDA Label Image

Figure 5 (Duloxetine 06)

Figure 5 (Duloxetine 06)
A line graph comparing the percentage of patients improved against the percent improvement in pain from baseline. The graph shows three treatment groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo, illustrating differences in pain improvement percentages across varying levels of pain reduction.*
FDA Label Image

Figure 6 (Duloxetine 07)

Figure 6 (Duloxetine 07)
A line graph depicting the percentage of patients improved plotted against the percent improvement in pain from baseline. The graph compares the effects of different Duloxetine doses (120 mg once daily, 60 mg once daily, 20 mg once daily) and a placebo control.*
FDA Label Image

Figure 7 (Image 01)

Figure 7 (Image 01)
A line chart comparing the percentage of patients improved relative to the percent improvement in pain from baseline. It features two lines: one for Cymbalta 60 mg once daily and one for placebo, showing the distribution of patient pain improvement percentages across these two treatments.*
FDA Label Image

Figure 8 (Duloxetine 08)

Figure 8 (Duloxetine 08)
A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline. It displays two data series: Placebo and Duloxetine (DUL) 60/120 mg once daily, with Duloxetine showing consistently higher pain improvement percentages across the measured range.*
FDA Label Image

Figure 9 (Duloxetine 09)

Figure 9 (Duloxetine 09)
A line graph comparing the percentage of patients improved against percent improvement in pain from baseline. The graph shows two lines representing placebo and DUL 60 mg once daily, illustrating patient improvement rates over a range of pain improvement percentages.*
FDA Label Image

Figure 10 (Duloxetine 10)

Figure 10 (Duloxetine 10)
A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine Delayed-Release Capsules 60/120 mg once daily and placebo. The graph shows two lines depicting treatment outcomes across various pain improvement thresholds.*
FDA Label Image

Label (Duloxetine 14)

Label (Duloxetine 14)
Label for Duloxetine Delayed-Release Capsules, USP 40 mg by BluePoint Laboratories. The label includes dosage information, storage instructions, and a 30-capsule count. It is marked Rx Only, with NDC 68001-368-04, and manufacturing details for TOWA Pharmaceutical Europe, S.L. in Spain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.